Literature DB >> 23669403

First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of "western" disease.

Jie Zhao1, Siew C Ng, Yuan Lei, Fengming Yi, Jin Li, Limin Yu, Kaifang Zou, Zili Dan, Meng Dai, Yijuan Ding, Min Song, Qingtao Mei, Xiangming Fang, Huimin Liu, Zhaohong Shi, Rui Zhou, Ming Xia, Qingming Wu, Zhifan Xiong, Wencheng Zhu, Langiong Deng, Michael A Kamm, Bing Xia.   

Abstract

BACKGROUND: Previously a disease of the West and rarely seen in China, inflammatory bowel disease (IBD) is now increasing in incidence in China. However, its true incidence is unknown. The incidence of IBD in Wuhan, a major city in central China, was investigated using population-based methods.
METHODS: A prospective, population-based IBD incidence study was conducted between January 1, 2010, and December 31, 2010. New IBD cases were identified by gastroenterologists and from hospital case records in 17 central hospitals covering the health care service of central Wuhan. Cases were confirmed by follow-up and assessed by a specialist IBD group every 3 months. The population at risk was 6,085,556.
RESULTS: Overall, 131 new cases of IBD were identified during the 1-year period, including 97 cases of ulcerative colitis (UC) and 34 cases of Crohn's disease (CD). The age-adjusted incidence for all IBD, UC, and CD were 1.96 per 100,000 (95% confidence interval [CI], 1.62-2.30 per 100,000), 1.45 (95% CI, 1.16-1.75), and 0.51 (95% CI, 0.33-0.68), respectively. CD affected the small bowel only in 15%, colon only in 24%, and ileocolonic in 61%. CD often presented with complicated phenotype: inflammatory (44%), stricturing (29%), and penetrating (24%). Among patients with UC, complications included proctitis (34.5%), left-sided colitis (44.6%), and extensive colitis (19.5%).
CONCLUSIONS: There is a substantial incidence of IBD in China. Although still lower than in the West, the emergence of IBD will necessitate specific health care planning and education and offers the possibility of identifying causative factors in a population with a rapidly increasing incidence.

Entities:  

Mesh:

Year:  2013        PMID: 23669403     DOI: 10.1097/MIB.0b013e31828a6551

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  53 in total

1.  Clinical presentation and treatment strategies for ulcerative colitis: A retrospective study of 247 inpatients.

Authors:  Yan-Cheng Dai; Ya-Li Zhang; Li-Juan Wang; Qian Guo; Kun Yang; Ren-Hao Ye; Zhi-Peng Tang
Journal:  Chin J Integr Med       Date:  2015-10-26       Impact factor: 1.978

Review 2.  The global burden of IBD: from 2015 to 2025.

Authors:  Gilaad G Kaplan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

3.  Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.

Authors:  Mingming Zhu; Xitao Xu; Qi Feng; Zhe Cui; Tianrong Wang; Yunqi Yan; Zhihua Ran
Journal:  Dig Dis Sci       Date:  2020-06-10       Impact factor: 3.199

4.  Emerging Trends of Inflammatory Bowel Disease in Asia.

Authors:  Siew C Ng
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-03

5.  Risk factors for initial surgery in patients with Crohn's disease in Central China.

Authors:  Min Chen; Fengming Yi; Feng Zhou; Meifang Huang; Jin Li; Wenfeng Yan; Lixia Li; Bing Xia
Journal:  Surg Today       Date:  2014-12-20       Impact factor: 2.549

Review 6.  Influence of environmental factors in the development of inflammatory bowel diseases.

Authors:  Evangelia Legaki; Maria Gazouli
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 7.  Inflammatory bowel diseases: Current problems and future tasks.

Authors:  Giovanni C Actis; Rinaldo Pellicano; Floriano Rosina
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 8.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

9.  The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment.

Authors:  Qiao Yu; Lingyun Wang; Shenghong Zhang; Ting Feng; Li Li; Baili Chen; Minhu Chen
Journal:  Blood Transfus       Date:  2016-02-24       Impact factor: 3.443

10.  Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives.

Authors:  Soo Jung Park; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.